Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadekinig alfa in NLRC4-MAS and XIAP Deficiency
NCT03113760Phase 3Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Jul 2017
- Primary completion
- Oct 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in NLRC4-associated macrophage activation syndrome (NLRC4-MAS) and X-linked inhibitor of apoptosis protein deficiency comparing Tadekinig alfa with Placebo (2 arms). Primary endpoint: Prevention of Flares at 16 weeks. Started Jul 2017; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
NLRC4-associated macrophage activation syndrome (NLRC4-MAS)X-linked inhibitor of apoptosis protein deficiency
Beyond the preview
Go deeper on NCT03113760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113760.